1887

Abstract

Combined daclatasvir (DCV)/asunaprevir (ASV) plus beclabuvir (BCV) treatment shows a high virological response for genotype 1b chronic hepatitis C patients. However, its efficacy for patients for whom previous direct-acting antiviral (DAA) therapy failed is not known. We analysed the efficacy of DCV/ASV/BCV treatment for HCV-infected mice and chronic hepatitis patients. Human hepatocyte chimaeric mice were injected with serum samples obtained from either a DAA-naïve patient or a DCV/ASV treatment failure and were then treated with DCV/ASV alone or in combination with BCV for 4 weeks. DCV/ASV treatment successfully eliminated the virus in DAA-naïve-patient HCV-infected mice. DCV/ASV treatment failure HCV-infected mice developed viral breakthrough during DCV/ASV treatment, with the emergence of NS5A-L31V/Y93H HCV resistance-associated variants (RAVs) being observed by direct sequencing. DCV/ASV/BCV treatment inhibited viral breakthrough in NS5A-L31V/Y93H-mutated HCV-infected mice, but HCV relapsed with the emergence of NS5B-P495S variants after the cessation of the treatment. The efficacy of the triple therapy was also analysed in HCV-infected patients; one DAA-naïve patient and four prior DAA treatment failures were treated with 12 weeks of DCV/ASV/BCV therapy. Sustained virological response was achieved in a DAA-naïve patient and one of the DCV/ASV treatment failures through DCV/ASV/BCV therapy; however, HCV relapse occurred in the other patients with prior DCV/ASV and/or sofosbuvir/ledipasvir treatment failures. DCV/ASV/BCV therapy seems to have limited efficacy for patients with NS5A RAVs for whom prior DAA treatment has failed.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001091
2018-06-19
2019-09-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/99/8/1058.html?itemId=/content/journal/jgv/10.1099/jgv.0.001091&mimeType=html&fmt=ahah

References

  1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333–1342 [CrossRef][PubMed]
    [Google Scholar]
  2. Sagnelli E, Coppola N, Scolastico C, Filippini P, Santantonio T et al. Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis. Hepatology 2000;32:1106–1110 [CrossRef][PubMed]
    [Google Scholar]
  3. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A et al. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999;85:2132–2137 [CrossRef][PubMed]
    [Google Scholar]
  4. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014;59:2083–2091 [CrossRef][PubMed]
    [Google Scholar]
  5. Morio R, Imamura M, Kawakami Y, Morio K, Kobayashi T et al. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. J Gastroenterol 2017;52:504–511 [CrossRef][PubMed]
    [Google Scholar]
  6. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015;15:645–653 [CrossRef][PubMed]
    [Google Scholar]
  7. Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L et al. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology 2015;61:1523–1532 [CrossRef][PubMed]
    [Google Scholar]
  8. Kumada H, Suzuki Y, Karino Y, Chayama K, Kawada N et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. J Gastroenterol 2017;52:520–533 [CrossRef][PubMed]
    [Google Scholar]
  9. Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 2016;151:70–86 [CrossRef][PubMed]
    [Google Scholar]
  10. Kan H, Imamura M, Uchida T, Hiraga N, Hayes CN et al. Protease inhibitor resistance remains even after mutant strains become undetectable by deep sequencing. J Infect Dis 2016;214:1687–1694 [CrossRef][PubMed]
    [Google Scholar]
  11. Yoshimi S, Imamura M, Murakami E, Hiraga N, Tsuge M et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol 2015;87:1913–1920 [CrossRef][PubMed]
    [Google Scholar]
  12. Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, Lawitz E et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014;146:420–429 [CrossRef][PubMed]
    [Google Scholar]
  13. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015;313:1736–1744 [CrossRef][PubMed]
    [Google Scholar]
  14. Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E et al. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. J Hepatol 2015;62:1204–1206 [CrossRef][PubMed]
    [Google Scholar]
  15. Poordad F, Sievert W, Mollison L, Bennett M, Tse E et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015;313:1728–1735 [CrossRef][PubMed]
    [Google Scholar]
  16. Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T et al. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients. Liver Int 2016;36:189–197 [CrossRef][PubMed]
    [Google Scholar]
  17. Toyota J, Karino Y, Suzuki F, Ikeda F, Ido A et al. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol 2017;52:385–395 [CrossRef][PubMed]
    [Google Scholar]
  18. Tateno C, Kawase Y, Tobita Y, Hamamura S, Ohshita H et al. Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA/SCID mice. PLoS One 2015;10:e0142145 [CrossRef][PubMed]
    [Google Scholar]
  19. Uchida T, Imamura M, Kan H, Hiraga N, Hayes CN et al. Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology. J Gen Virol 2017;98:1040–1047 [CrossRef][PubMed]
    [Google Scholar]
  20. Kan H, Hiraga N, Imamura M, Hayes CN, Uchida T et al. Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice. Antivir Ther 2016;21:307–315 [CrossRef][PubMed]
    [Google Scholar]
  21. Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y et al. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. J Med Virol 2017;89:284–290 [CrossRef][PubMed]
    [Google Scholar]
  22. Liu M, Tuttle M, Gao M, Lemm JA. Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes. Antimicrob Agents Chemother 2014;58:7416–7423 [CrossRef][PubMed]
    [Google Scholar]
  23. Kan H, Imamura M, Kawakami Y, Daijo K, Teraoka Y et al. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients. J Med Virol 2017;89:1963–1972 [CrossRef][PubMed]
    [Google Scholar]
  24. Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K et al. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 2018;53:566–575 [CrossRef][PubMed]
    [Google Scholar]
  25. Poordad F, Pol S, Asatryan A, Buti M, Shaw D et al. Glecaprevir/pibrentasvir in patients with HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Hepatology 2017;67:1260
    [Google Scholar]
  26. Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman CAM et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology 2017;66:1083–1089 [CrossRef][PubMed]
    [Google Scholar]
  27. Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y et al. Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus. Hepatology 2017;65:1803–1809 [CrossRef][PubMed]
    [Google Scholar]
  28. Halfon P, Scholtès C, Izopet J, Larrat S, Trimoulet P et al. Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world. J Hepatol 2018;68:595–597 [CrossRef][PubMed]
    [Google Scholar]
  29. Hiraga N, Imamura M, Tsuge M, Noguchi C, Takahashi S et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. FEBS Lett 2007;581:1983–1987 [CrossRef][PubMed]
    [Google Scholar]
  30. Yoshimi S, Ochi H, Murakami E, Uchida T, Kan H et al. Rapid, sensitive, and accurate evaluation of drug resistant mutant (NS5A-Y93H) strain frequency in genotype 1b HCV by invader assay. PLoS One 2015;10:e0130022 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001091
Loading
/content/journal/jgv/10.1099/jgv.0.001091
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error